Trial · NCT03691623
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Part 1: EDP-938 600 mg | 39 | |
| Overall Study | STARTED | Part 1: EDP-938 500 mg Then 300 mg | 38 | |
| Overall Study | STARTED | Part 1: Placebo | 38 | |
| Overall Study | STARTED | Part 2: EDP-938 600 mg Then 300 mg | 21 | |
| Overall Study | STARTED | Part 2: EDP-938 400 mg Then 200 mg | 21 | |
| Overall Study | STARTED | Part 2: Placebo | 21 | |
| Overall Study | Inoculated With Challenge Virus | Part 1: EDP-938 600 mg | 39 | |
| Overall Study | Inoculated With Challenge Virus | Part 1: EDP-938 500 mg Then 300 mg | 38 | |
| Overall Study | Inoculated With Challenge Virus | Part 1: Placebo | 38 | |
| Overall Study | Inoculated With Challenge Virus | Part 2: EDP-938 600 mg Then 300 mg | 21 | |
| Overall Study | Inoculated With Challenge Virus | Part 2: EDP-938 400 mg Then 200 mg | 21 | |
| Overall Study | Inoculated With Challenge Virus | Part 2: Placebo | 21 | |
| Overall Study | Received Treatment | Part 1: EDP-938 600 mg | 38 | |
| Overall Study | Received Treatment | Part 1: EDP-938 500 mg Then 300 mg | 38 | |
| Overall Study | Received Treatment | Part 1: Placebo | 38 | |
| Overall Study | Received Treatment | Part 2: EDP-938 600 mg Then 300 mg | 21 | |
| Overall Study | Received Treatment | Part 2: EDP-938 400 mg Then 200 mg | 21 | |
| Overall Study | Received Treatment | Part 2: Placebo | 21 | |
| Overall Study | COMPLETED | Part 1: EDP-938 600 mg | 39 | |
| Overall Study | COMPLETED | Part 1: EDP-938 500 mg Then 300 mg | 38 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03691623/flow